Adele Mucci

Adele Mucci

Auto-generated profile, based on publicly available information

Adele Mucci

Cellular Immunotherapy Program, Mass General Brigham Cancer Institute, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CHChristine Happle
Christine Happle
NLNico Lachmann
Nico Lachmann
Jelena SkuljecJelena Skuljec
Jelena Skuljec
MWMartin Wetzke
Martin Wetzke
MAMania Ackermann
Mania Ackermann
GHGesine Hansen
Gesine Hansen
Macrophage progenitors are an effective and long-lasting therapy of hereditary pulmonary alveolar proteinosis.

15 January 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
NLNico Lachmann
Nico Lachmann
CHChristine Happle
Christine Happle
MAMania Ackermann
Mania Ackermann
DLDoreen Lüttge
Doreen Lüttge
MWMartin Wetzke
Martin Wetzke
TMThomas Moritz
Thomas Moritz
Rationale: Hereditary pulmonary alveolar proteinosis (hPAP) caused by granulocyte–macrophage colony–stimulating factor (GM-CSF) receptor α-chain (CSF2RA) deficiency is a rare, life-threatening lung disease characterized by accumulation of proteins and phospholipids in the alveolar spaces. The disease is caused by a functional insufficiency of alveolar macrophages, which require GM-CSF signaling for terminal differentiation and effective degradation of alveolar proteins and phospholipids. Therapeutic options are extremely limited, and the pathophysiology underlying the defective protein degradation in hPAP alveolar macrophages remains poorly understood. Objectives: To further elucidate the cellular mechanisms underlying hPAP and evaluate novel therapeutic strategies, we here investigated the potential of hPAP patient-derived induced pluripotent stem cell (PAP-iPSCs) derived monocytes and macrophages. Methods: Patient-specific PAP-iPSCs were generated from CD34+ bone marrow cells of a CSF2RA-deficient patient with PAP. We assessed pluripotency, chromosomal integrity, and genetic correction of established iPSC lines. On hematopoietic differentiation, genetically corrected or noncorrected monocytes and macrophages were investigated in GM-CSF–dependent assays. Measurements and Main Results: Although monocytes and macrophages differentiated from noncorrected PAP-iPSCs exhibited distinct defects in GM-CSF–dependent functions, such as perturbed CD11b activation, phagocytic activity, and STAT5 phosphorylation after GM-CSF exposure and lack of GM-CSF uptake, these defects were fully repaired on lentiviral gene transfer of a codon-optimized CSF2RA-cDNA. Conclusions: These data establish PAP-iPSC–derived monocytes and macrophages as a valid in vitro disease model of CSF2RA-deficient PAP, and introduce gene-corrected iPSC-derived monocytes and macrophages as a potential autologous cell source for innovative therapeutic strategies. Transplantation of such cells to patients with hPAP could serve as a paradigmatic proof for the potential of iPSC-derived cells in clinical gene therapy.

1 August 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CHChristine Happle
Christine Happle
NLNico Lachmann
Nico Lachmann
MAMania Ackermann
Mania Ackermann
AMAnja Mirenska
Anja Mirenska
GGGudrun Göhring
Gudrun Göhring
GHGesine Hansen
Gesine Hansen
Rationale: Although the transplantation of induced pluripotent stem cell (iPSC)–derived cells harbors enormous potential for the treatment of pulmonary diseases, in vivo data demonstrating clear therapeutic benefits of human iPSC–derived cells in lung disease models are missing. Objectives: We have tested the therapeutic potential of iPSC-derived macrophages in a humanized disease model of hereditary pulmonary alveolar proteinosis (PAP). Hereditary PAP is caused by a genetic defect of the GM-CSF (granulocyte–macrophage colony–stimulating factor) receptor, which leads to disturbed macrophage differentiation and protein/surfactant degradation in the lungs, subsequently resulting in severe respiratory insufficiency. Methods: Macrophages derived from human iPSCs underwent intrapulmonary transplantation into humanized PAP mice, and engraftment, in vivo differentiation, and therapeutic efficacy of the transplanted cells were analyzed. Measurements and Main Results: On intratracheal application, iPSC-derived macrophages engrafted in the lungs of humanized PAP mice. After 2 months, transplanted cells displayed the typical morphology, surface markers, functionality, and transcription profile of primary human alveolar macrophages. Alveolar proteinosis was significantly reduced as demonstrated by diminished protein content and surfactant protein D levels, decreased turbidity of the BAL fluid, and reduced surfactant deposition in the lungs of transplanted mice. Conclusions: We here demonstrate for the first time that pulmonary transplantation of human iPSC–derived macrophages leads to pulmonary engraftment, their in situ differentiation to an alveolar macrophage phenotype, and a reduction of alveolar proteinosis in a humanized PAP model. To our knowledge, this finding presents the first proof-of-concept for the therapeutic potential of human iPSC-derived cells in a pulmonary disease and may have profound implications beyond the rare disease of PAP.

25 October 2016 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
ELElena Lopez-Rodriguez
Elena Lopez-Rodriguez
GGGemma Gay-Jordi
Gemma Gay-Jordi
AMAdele Mucci
Adele Mucci
NLNico Lachmann
Nico Lachmann
ASAnna Serrano-Mollar
Anna Serrano-Mollar

1 February 2014 in Biomaterials
Verified
Journal Article
Closed access
MAMania Ackermann
Mania Ackermann
NLNico Lachmann
Nico Lachmann
SHSusann Hartung
Susann Hartung
REReto Eggenschwiler
Reto Eggenschwiler
NPNils Pfaff
Nils Pfaff
TMThomas Moritz
Thomas Moritz

1 September 2018 in Stem Cell Reports
Verified
Journal Article
Open access
AMAdele Mucci
Adele Mucci
ELElena Lopez-Rodriguez
Elena Lopez-Rodriguez
MHMiriam Hetzel
Miriam Hetzel
SLSerena Liu
Serena Liu
TSTakuji Suzuki
Takuji Suzuki
TMThomas Moritz
Thomas Moritz
Induced pluripotent stem cell (iPSC)-derived hematopoietic cells represent a highly attractive source for cell and gene therapy. Given the longevity, plasticity, and self-renewal potential of distinct macrophage subpopulations, iPSC-derived macrophages (iPSC-Mφ) appear of particular interest in this context. We here evaluated the airway residence, plasticity, and therapeutic efficacy of iPSC-Mφ in a murine model of hereditary pulmonary alveolar proteinosis (herPAP). We demonstrate that single pulmonary macrophage transplantation (PMT) of 2.5-4 × 106 iPSC-Mφ yields efficient airway residence with conversion of iPSC-Mφ to an alveolar macrophage (AMφ) phenotype characterized by a distinct surface marker and gene expression profile within 2 months. Moreover, PMT significantly improves alveolar protein deposition and other critical herPAP disease parameters. Thus, our data indicate iPSC-Mφ as a source of functional macrophages displaying substantial plasticity and therapeutic potential that upon pulmonary transplantation will integrate into the lung microenvironment, adopt an AMφ phenotype and gene expression pattern, and profoundly ameliorate pulmonary disease phenotypes.